Article Text

Download PDFPDF
Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy
  1. P Zeni1,
  2. E Finger2,
  3. M A Scheinberg3
  1. 1
    Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, São Paulo, Brazil
  2. 2
    Parasitology Section, Faculty of Medical Sciences, São Paulo, Brazil
  3. 3
    Internal Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil
  1. Dr Morton A Scheinberg, Internal Medicine, Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652-900, Brazil; morton{at}osite.com.br

Statistics from Altmetric.com

Livedoid vasculopathy (LV) is a chronic recurrent painful cutaneous disease characterised by foci of purpuric lesions that convert to shallow ulcerations that progress to atrophic scar-like plaques mixed with telangiectasia and hyperpigmentation.1 2 Although of unknown aetiology, LV strongly correlates with immune complex associated diseases that lead to dermal vessel occlusion,3 and its histology consistently exhibits inflammatory infiltrates.4 Laboratory abnormalities consist essentially of a hypercoagulable state.5 Treatment of LV is usually empirical and based on immunosuppression with high-dose steroids, azathioprine, methotrexate and anticoagulation.6 In this report, we present a patient …

View Full Text

Footnotes

  • Competing interests: None.

  • Patient consent: Informed consent has been obtained for the publication of the patient’s details in this report.